Max Robinson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9332007/publications.pdf

Version: 2024-02-01

68 papers

3,532 citations

26 h-index 58 g-index

69 all docs 69 docs citations

69 times ranked 5248 citing authors

#	Article	IF	CITATIONS
1	Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet, The, 2019, 393, 51-60.	6.3	697
2	PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. New England Journal of Medicine, 2016, 374, 1444-1454.	13.9	503
3	Evaluation of Human Papilloma Virus Diagnostic Testing in Oropharyngeal Squamous Cell Carcinoma: Sensitivity, Specificity, and Prognostic Discrimination. Clinical Cancer Research, 2011, 17, 6262-6271.	3.2	304
4	PATHOS: a phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer. BMC Cancer, 2015, 15, 602.	1.1	171
5	Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. Nature Genetics, 2016, 48, 1544-1550.	9.4	164
6	Evaluation of human papillomavirus testing for squamous cell carcinoma of the tonsil in clinical practice. Journal of Clinical Pathology, 2011, 64, 308-312.	1.0	129
7	HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology. Cancer Research, 2016, 76, 6598-6606.	0.4	128
8	Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing. Oral Oncology, 2010, 46, 492-496.	0.8	104
9	Human Papillomavirus-associated oropharyngeal cancer: an observational study of diagnosis, prevalence and prognosis in a UK population. BMC Cancer, 2013, 13, 220.	1.1	74
10	HPV Specific Testing: A Requirement for Oropharyngeal Squamous Cell Carcinoma Patients. Head and Neck Pathology, 2012, 6, 83-90.	1.3	73
11	The use of digital pathology and image analysis in clinical trials. Journal of Pathology: Clinical Research, 2019, 5, 81-90.	1.3	71
12	Combined effects of smoking and HPV16 in oropharyngeal cancer. International Journal of Epidemiology, 2016, 45, 752-761.	0.9	67
13	Oncogenic human papillomavirus-associated nasopharyngeal carcinoma: an observational study of correlation with ethnicity, histological subtype and outcome in a UK population. Infectious Agents and Cancer, 2013, 8, 30.	1.2	64
14	Squamous cell carcinoma of the head and neck outside the oropharynx is rarely human papillomavirus related. Laryngoscope, 2014, 124, 2739-2744.	1.1	55
15	PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomographya€"computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment, 2017, 21, 1-122.	1.3	52
16	Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach. British Journal of Cancer, 2019, 120, 827-833.	2.9	51
17	The influence of smoking, age and stage at diagnosis on the survival after larynx, hypopharynx and oral cavity cancers in <scp>E</scp> urope: The <scp>ARCAGE</scp> study. International Journal of Cancer, 2018, 143, 32-44.	2.3	50
18	Squamous cell carcinoma of the oral cavity rarely harbours oncogenic human papillomavirus. Oral Oncology, 2011, 47, 698-701.	0.8	49

#	Article	IF	CITATIONS
19	Polymorphous low-grade adenocarcinoma of the head and neck. Current Opinion in Otolaryngology and Head and Neck Surgery, 2008, 16, 163-169.	0.8	44
20	The increasing clinical relevance of human papillomavirus type 16 (HPV-16) infection in oropharyngeal cancer. British Journal of Oral and Maxillofacial Surgery, 2011, 49, 423-429.	0.4	42
21	IGF-1R expression is associated with HPV-negative status and adverse survival in head and neck squamous cell cancer. Carcinogenesis, 2015, 36, 648-655.	1.3	41
22	Geographic variation in human papillomavirus–related oropharyngeal cancer: Data from 4 multinational randomized trials. Head and Neck, 2016, 38, E1863-9.	0.9	41
23	Collagen Induces a More Proliferative, Migratory and Chemoresistant Phenotype in Head and Neck Cancer via DDR1. Cancers, 2019, 11, 1766.	1.7	36
24	Development and external validation of nomograms in oropharyngeal cancer patients with known HPV-DNA status: a European Multicentre Study (OroGrams). British Journal of Cancer, 2018, 118, 1672-1681.	2.9	32
25	Transoral robotic surgery for residual and recurrent oropharyngeal cancers: Exploratory study of surgical innovation using the IDEAL framework for earlyâ€phase surgical studies. Head and Neck, 2018, 40, 512-525.	0.9	31
26	The Formation of Endoderm-Derived Taste Sensory Organs Requires a Pax9-Dependent Expansion of Embryonic Taste Bud Progenitor Cells. PLoS Genetics, 2014, 10, e1004709.	1.5	30
27	Small Cell Neuroendocrine Carcinoma of the Oropharynx Harbouring Oncogenic HPV-Infection. Head and Neck Pathology, 2014, 8, 127-131.	1.3	28
28	Transoral laser microsurgery for oropharyngeal squamous cell carcinoma: A paradigm shift in therapeutic approach. Head and Neck, 2016, 38, 1263-1270.	0.9	28
29	HPV sensitizes OPSCC cells to cisplatin-induced apoptosis by inhibiting autophagy through E7-mediated degradation of AMBRA1. Autophagy, 2021, 17, 2842-2855.	4.3	25
30	Twenty-first-century oral hairy leukoplakiaâ€"a nonâ€"HIV-associated entity. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2015, 119, 326-332.	0.2	21
31	Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work. Journal of Pathology: Clinical Research, 2019, 5, 91-99.	1.3	21
32	A digital score of tumourâ€associated stroma infiltrating lymphocytes predicts survival in head and neck squamous cell carcinoma. Journal of Pathology, 2022, 256, 174-185.	2.1	20
33	Multicentric human papillomavirus–associated head and neck squamous cell carcinoma. Head and Neck, 2015, 37, 202-208.	0.9	17
34	Predicting the clinical outcome of oral potentially malignant disorders using transcriptomic-based molecular pathology. British Journal of Cancer, 2021, 125, 413-421.	2.9	16
35	Salivary gland swellings. BMJ, The, 2012, 345, e6794-e6794.	3.0	15
36	Patients with HPV-related tonsil squamous cell carcinoma rarely harbour oncogenic HPV infection at other pharyngeal sites. Oral Oncology, 2014, 50, 241-246.	0.8	14

#	Article	IF	Citations
37	Comparison of Molecular Assays for HPV Testing in Oropharyngeal Squamous Cell Carcinomas: A Population-Based Study in Northern Ireland. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 31-38.	1.1	14
38	Human Papillomavirus Testing in Head and Neck Squamous Cell Carcinoma: Best Practice for Diagnosis. Methods in Molecular Biology, 2014, 1180, 237-255.	0.4	14
39	Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncology, The, 2021, 22, e435-e445.	5.1	13
40	Ganglioneuroblastic Transformation in Olfactory Neuroblastoma. Head and Neck Pathology, 2012, 6, 150-155.	1.3	12
41	Changes in Epidermal Growth Factor Receptor Gene Copy Number during Oral Carcinogenesis. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 927-935.	1.1	12
42	The important role of the histopathologist in clinical trials: challenges and approaches to tackle them. Histopathology, 2020, 76, 942-949.	1.6	11
43	Training and accreditation standards for pathologists undertaking clinical trial work. Journal of Pathology: Clinical Research, 2019, 5, 100-107.	1.3	10
44	Dysplasia and DNA ploidy to prognosticate clinical outcome in oral potentially malignant disorders. Journal of Oral Pathology and Medicine, 2021, 50, 200-209.	1.4	10
45	Gene expression changes associated with malignant transformation of oral potentially malignant disorders. Journal of Oral Pathology and Medicine, 2021, 50, 60-67.	1.4	10
46	Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer. Nature Communications, 2021, 12, 5945.	5.8	10
47	Transoral robotic surgery and neck dissection alone for head and neck squamous cell carcinoma: Influence of resection margins on oncological outcomes. Oral Oncology, 2022, 130, 105909.	0.8	10
48	Intraoperative Sentinel Lymph Node Evaluation: Implications of Cytokeratin 19 Expression for the Adoption of OSNA in Oral Squamous Cell Carcinoma. Annals of Surgical Oncology, 2016, 23, 4042-4048.	0.7	9
49	HPV Testing of Head and Neck Cancer in Clinical Practice. Recent Results in Cancer Research, 2017, 206, 101-111.	1.8	8
50	Trans-oral robotic surgery for oropharyngeal cancer: implications for pathologists. Diagnostic Histopathology, 2020, 26, 181-187.	0.2	8
51	Salivary gland swellings. Clinical Otolaryngology, 2013, 38, 58-65.	0.6	7
52	Essential characterisation of human papillomavirus positive head and neck cancer cell lines. Oral Oncology, 2020, 103, 104613.	0.8	7
53	Concurrent HPV-related oropharyngeal carcinoma in four couples. Oral Oncology, 2018, 86, 33-37.	0.8	6
54	Clinico-pathological features of oropharyngeal squamous cell carcinomas in Malaysia with reference to HPV infection. Infectious Agents and Cancer, 2018, 13, 21.	1.2	6

#	Article	IF	CITATIONS
55	Primary transoral robotic surgery +/―adjuvant therapy for oropharyngeal squamous cell carcinoma—A large observational singleâ€centre series from the United Kingdom. Clinical Otolaryngology, 2021, 46, 1005-1012.	0.6	6
56	The clinical utility of contemporary oral epithelial dysplasia grading systems. Journal of Oral Pathology and Medicine, 2022, 51, 180-187.	1.4	6
57	A service evaluation of the diagnostic testing for mucous membrane pemphigoid in a UK oral medicine unit. Journal of Oral Pathology and Medicine, 2020, 49, 687-692.	1.4	5
58	Human papilloma virus detection in oropharyngeal carcinomas with in situ hybridisation using hand crafted morphological features and deep central attention residual networks. Computerized Medical Imaging and Graphics, 2021, 88, 101853.	3.5	5
59	Human papillomavirus testing in diagnostic head and neck histopathology. Diagnostic Histopathology, 2015, 21, 77-84.	0.2	4
60	Robotic lateral oropharyngectomy following diagnostic tonsillectomy is oncologically safe in patients with high risk human papillomavirus related squamous cell cancer. European Archives of Oto-Rhino-Laryngology, 2018, 275, 1853-1860.	0.8	4
61	Recommendations for cellular and molecular pathology input into clinical trials: a systematic review and metaâ€aggregation. Journal of Pathology: Clinical Research, 2021, 7, 191-202.	1.3	4
62	SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasiaâ€"a phase II randomised control trial study protocol. Trials, 2021, 22, 428.	0.7	4
63	PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT) lournal of Clinical Oncology, 2015, 33, 6009-6009.	0.8	4
64	Primary carcinoma ex-pleomorphic adenoma of anterior commissure of the larynx. Oral Oncology, 2018, 84, 131-133.	0.8	2
65	Quality Assessment Across Disciplines in Head and Neck Cancer Treatment Diagnostic Pathology in HNSCC. Frontiers in Oncology, 2020, 10, 364.	1.3	2
66	Assessment of clinical trial protocols for pathology content using the <scp>SPIRITâ€Path</scp> guidelines highlights areas for improvement. Journal of Pathology: Clinical Research, 0, , .	1.3	1
67	Should we test for high-risk human papilloma virus in patients with oral dysplasia?. British Journal of Oral and Maxillofacial Surgery, 2016, 54, 590-591.	0.4	0
68	Desperately seeking the primary: a systematic approach to assessing malignant cervical lymphadenopathy. Diagnostic Histopathology, 2022, , .	0.2	O